Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions

被引:7
作者
Bot, Adrian [1 ]
Marincola, Francesco [2 ]
Smith, Kent A. [3 ]
机构
[1] Kite Pharma Inc, Santa Monica, CA USA
[2] Sidra Med & Res Ctr, Doha, Qatar
[3] Dockside Consultants, Ventura, CA USA
关键词
adoptive T-cell therapy; cancer vaccines; combinatorial therapies; engineered T cells; immune checkpoint blockade; immunotherapy; minimal residual disease; tumor infiltrating lymphocytes; ADOPTIVE CELL TRANSFER; TUMOR-INFILTRATING LYMPHOCYTES; CHRONIC MYELOID-LEUKEMIA; T-CELL; DENDRITIC CELLS; METASTATIC MELANOMA; IN-VIVO; PEPTIDE VACCINATION; ANTITUMOR-ACTIVITY; CLINICAL-TRIAL;
D O I
10.1586/14760584.2013.836908
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Based on lessons learned with various immune interventions, this review aims to provide a constructive framework for repositioning therapeutic cancer vaccination. Intensive research throughout the past decade has identified key hurdles interfering with the efficacy of cancer vaccines. The vaccination concept still holds promise if positioned appropriately in minimal residual disease and select early disease stage cancer indications. However, in advanced cancer, it must be integrated with complementary immune interventions to ensure reconstruction of a functional immune repertoire and simultaneous blockade of immune inhibiting mechanisms. Vaccination could render complex and integrative immune interventions simpler, safer and more effective. The near future will witness an explosion of activities in the cancer immunotherapy arena, witnessing a rational repositioning of vaccines rather than their extinction.
引用
收藏
页码:1219 / 1234
页数:16
相关论文
共 135 条
  • [1] Abate-Daga D., 2013, Blood
  • [2] Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients
    Alfaro, Carlos
    Perez-Gracia, Jose L.
    Suarez, Natalia
    Rodriguez, Javier
    Fernandez de Sanmamed, Miguel
    Sangro, Bruno
    Martin-Algarra, Salvador
    Calvo, Alfonso
    Redrado, Miriam
    Agliano, Alice
    Gonzalez, Alvaro
    Rodriguez, Inmaculada
    Bolanos, Elixabet
    Hervas-Stubbs, Sandra
    Perez-Calvo, Javier
    Benito, Alberto
    Penuelas, Ivan
    Vigil, Carmen
    Richter, Jose
    Martinez-Forero, Ivan
    Melero, Ignacio
    [J]. JOURNAL OF IMMUNOLOGY, 2011, 187 (11) : 6130 - 6142
  • [3] [Anonymous], 2012, 35 ANN CTRC AACR SAN
  • [4] Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer
    Arens, Ramon
    van Hall, Thorbald
    van der Burg, Sjoerd H.
    Ossendorp, Ferry
    Melief, Cornelis J. M.
    [J]. SEMINARS IN IMMUNOLOGY, 2013, 25 (02) : 182 - 190
  • [5] Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery
    Asavaroengchai, W
    Kotera, Y
    Mulé, JJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (02) : 931 - 936
  • [6] CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
    Beatty, Gregory L.
    Chiorean, Elena G.
    Fishman, Matthew P.
    Saboury, Babak
    Teitelbaum, Ursina R.
    Sun, Weijing
    Huhn, Richard D.
    Song, Wenru
    Li, Dongguang
    Sharp, Leslie L.
    Torigian, Drew A.
    O'Dwyer, Peter J.
    Vonderheide, Robert H.
    [J]. SCIENCE, 2011, 331 (6024) : 1612 - 1616
  • [7] Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines
    Benavides, Linda C.
    Sears, Alan K.
    Gates, Jeremy D.
    Clifton, Guy T.
    Clive, Kevin S.
    Carmichael, Mark G.
    Holmes, Jarrod P.
    Mittendorf, Elizabeth A.
    Ponniah, Sathibalan
    Peoples, George E.
    [J]. EXPERT REVIEW OF VACCINES, 2011, 10 (02) : 201 - 210
  • [8] Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)
    Borrello, Ivan M.
    Levitsky, Hyam I.
    Stock, Wendy
    Sher, Dorie
    Qin, Lu
    DeAngelo, Daniel J.
    Alyea, Edwin P.
    Stone, Richard M.
    Damon, Lloyd E.
    Linker, Charles A.
    Maslyar, Daniel J.
    Hege, Kristen M.
    [J]. BLOOD, 2009, 114 (09) : 1736 - 1745
  • [9] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2455 - 2465
  • [10] Adoptive T cell therapy of cancer
    Brenner, Malcolm K.
    Heslop, Helen E.
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2010, 22 (02) : 251 - 257